Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

globenewswire.com
BIIB Biogen's Litifilimab (BIIB059) is showing promise in Phase III trials for cutaneous lupus erythematosus, targeting key inflammatory pathways. Positive trial results could significantly advance treatment options. AMGN Amgen's Daxdilimab (HZN-7734) is being explored for various autoimmune disorders including cutaneous lupus erythematosus. Positive Phase II results in DLE suggest potential for future success. BMY Bristol Myers Squibb's SOTYKTU is mentioned as an emerging therapy for cutaneous lupus erythematosus, indicating potential market expansion and new treatment options. IMVT Immunovant Sciences' IMVT-1402 is listed as an emerging therapy for cutaneous lupus erythematosus, suggesting potential for growth and new treatment avenues in the market. AZN AstraZeneca's Anifrolumab (SAPHNELO), approved for SLE, is being evaluated for cutaneous lupus erythematosus, indicating efforts to expand its therapeutic applications and market reach. MRK Merck's Enpatoran is mentioned as an emerging therapy for cutaneous lupus erythematosus, suggesting potential for market expansion and new treatment options. CTNT Century Therapeutics' CNTY-101 is identified as an emerging therapy for cutaneous lupus erythematosus, indicating potential market growth and new treatment avenues. REGN Regeneron Pharmaceuticals is not explicitly mentioned in the article regarding cutaneous lupus erythematosus or related pipeline developments. GILD Gilead Sciences is mentioned in the context of a Cutaneous Lupus Erythematosus Pipeline Insight report, but no specific drug or sentiment is detailed for the company.

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight New York, USA, June 22, 2026 (GLOBE NEWSWIRE) -- Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune and dermatological disorders. The introduction of novel targeted therapies such as Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), and others, and biologics, along with ongoing clinical research, is expanding the treatment landscape for CLE patients.

Recently published Cutaneous Lupus Erythematosus Market Insights report includes a comprehensive understanding of current treatment practices, cutaneous lupus erythematosus emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Cutaneous Lupus Erythematosus Market Summary

Discover cutaneous lupus erythematosus market growth opportunities @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market

Key Factors Driving the Growth of the Cutaneous Lupus Erythematosus Market

Aparna Thakur, project manager of forecasting at DelveInsight, said that the advances in understanding disease pathogenesis, particularly the role of type I interferon signaling and plasmacytoid dendritic cells, have led to emerging therapies under investigation, including litifilimab and deucravacitinib, which may expand future options for refractory disease.

Cutaneous Lupus Erythematosus Market Analysis

Learn more about disease-modifying therapies for cutaneous lupus erythematosus @ Cutaneous Lupus Erythematosus Treatment Market

Cutaneous Lupus Erythematosus Competitive Landscape

Some of the CLE drugs under development include Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), Anifrolumab (SAPHNELO) (AstraZeneca), Enpatoran (Merck), and others.

Biogen’s Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody designed to target BDCA2 expressed on plasmacytoid dendritic cells. Through BDCA2 engagement, the therapy suppresses the release of type I interferons and other inflammatory mediators that contribute to the development and progression of both systemic and cutaneous lupus. Litifilimab is currently under investigation in the Phase III AMETHYST trial (NCT05531565), which is evaluating its safety and efficacy in patients with active subacute or chronic cutaneous lupus erythematosus (CLE), regardless of the presence of systemic disease, who have not responded adequately to or cannot tolerate antimalarial treatment. Results from this study are anticipated to play a significant role in advancing targeted treatment options for CLE, with key findings expected in 2027.

Amgen/Horizon Therapeutics’ Daxdilimab (HZN-7734), previously known as VIB7734, is an anti-ILT7 monoclonal antibody that selectively depletes plasmacytoid dendritic cells implicated in autoimmune inflammation. By reducing these cells, daxdilimab aims to disrupt inflammatory pathways responsible for tissue damage across multiple autoimmune disorders. Beyond cutaneous lupus, the therapy is being explored for indications such as systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE), and alopecia areata, with future development plans extending to dermatomyositis and lupus nephritis. In 2026, Amgen (formerly Horizon Therapeutics) reported that its Phase II study in DLE concluded ahead of schedule after achieving enrollment targets, with findings demonstrating improvements in disease severity.

AstraZeneca’s Anifrolumab (SAPHNELO) is a fully human monoclonal antibody that targets the type I interferon receptor subunit 1, thereby inhibiting type I interferon signaling—a central driver of lupus-associated immune dysregulation. Approved as an intravenous treatment for SLE in the United States, Europe, and Japan, SAPHNELO continues to be evaluated by AstraZeneca across a broader range of lupus-related conditions, including cutaneous lupus erythematosus, as part of efforts to expand its therapeutic applications.

The anticipated launch of these emerging cutaneous lupus erythematosus therapies are poised to transform the cutaneous lupus erythematosus market landscape in the coming years. As these cutting-edge cutaneous lupus erythematosus therapies continue to mature and gain regulatory approval, they are expected to reshape the cutaneous lupus erythematosus market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about emerging cutaneous lupus erythematosus therapies, visit @ Cutaneous Lupus Erythematosus Medication

Recent Developments in the Cutaneous Lupus Erythematosus Market

What is Cutaneous Lupus Erythematosus?

Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disorder characterized by inflammation of the skin resulting from an abnormal immune response. It can occur independently or as part of systemic lupus erythematosus (SLE) and encompasses several clinical subtypes, including acute, subacute, and chronic cutaneous lupus erythematosus. Patients commonly present with photosensitive skin lesions, rashes, plaques, or scarring, predominantly affecting sun-exposed areas such as the face, scalp, neck, and arms. The disease can significantly impair quality of life due to its visible manifestations, potential for permanent scarring, and associated psychological burden. While the exact etiology remains unclear, genetic predisposition, environmental triggers such as ultraviolet radiation, and immune dysregulation are recognized contributors to disease development. Early diagnosis and appropriate management are essential to control disease activity, prevent irreversible skin damage, and improve patient outcomes.

Cutaneous Lupus Erythematosus Epidemiology Segmentation

The cutaneous lupus erythematosus epidemiology section provides insights into the historical and current cutaneous lupus erythematosus patient pool and forecasted trends for the leading markets. Chronic CLE is the most common subtype, accounting for approximately 70–80% of all CLE cases. Additionally, around 20–25% of patients with SLE may exhibit features of chronic cutaneous involvement.

The cutaneous lupus erythematosus market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand the future of cutaneous lupus erythematosus treatment @ Cutaneous Lupus Erythematosus Treatment Options

Scope of the Cutaneous Lupus Erythematosus Market Report

Discover more about next-generation CLE drugs @ Cutaneous Lupus Erythematosus Clinical Trials

Table of Contents

Related Reports

Cutaneous Lupus Erythematosus Clinical Trial Analysis

Cutaneous Lupus Erythematosus Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cutaneous Lupus Erythematosus companies, including Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others.

Systemic Lupus Erythematosus Market

Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, and others.

Systemic Lupus Erythematosus Clinical Trial Analysis

Systemic Lupus Erythematosus Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including Roche, Biogen, Viatris Inc., Novartis, Qilu Pharmaceutical, ImmuPharma, Beijing Mabworks Biotech Co., Ltd., Zenas Biopharma, AbbVie, Beijing InnoCare Pharma Tech Co., Ltd., Alumis Inc., Galapagos NV, Palleon Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Johnson & Johnson, Merck KGaA, Resolve Therapeutics, ILTOO Pharma, Argenx, Cartesian Therapeutics, Keymed Biosciences Co., Ltd, BioSenic, Eisai, Vertex Pharmaceuticals, Kyverna Therapeutics, Miltenyi Biomedicine, Astrazeneca, Otsuka Pharmaceutical, Fresh Tracks Therapeutics, and others.

Lupus Nephritis Market

Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including Roche, Novartis, Alexion Pharmaceuticals, AstraZeneca, Cabaletta Bio, AbelZeta, Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GlaxoSmithKline, and others.

IgA Nephropathy Market

IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key IgAN companies including Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.